BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Veloxis Pharmaceuticals A/S (VELO) Publishes Annual Report 2011


3/7/2012 9:45:15 AM

HORSHOLM, Denmark, March 7, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2011. The annual report has been prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

This company announcement should be read in conjunction with Veloxis' annual report 2011 published separately today.

Full Year 2011 Highlights

  • Positive phase III results in the LCP-Tacro Trial in stable kidney transplant patients which met all primary efficacy and safety endpoints.

  • Award of a DKK 3.9 million grant from The Danish National Advanced Technology Foundation to support development of an oral chemotherapy agent.

  • Company name changed from LifeCycle Pharma.

  • Licensing of US commercial FenoglideĀ® (fenofibrate) rights to Santarus and settlement of Impax patent litigation.

  • Veloxis and Athena Drug Delivery Solutions Pvt. Ltd. partnership to develop, manufacture and commercialize Veloxis' investigational drug AtorFen (Fenofibrate-Atorvastin fixed dose combination) in certain emerging markets.

  • During 2011, Veloxis had no revenue compared to DKK 1.5 million in 2010. Revenue in 2010 consisted of payments under Veloxis' collaboration agreements.

  • Research and development costs increased by DKK 11.6 million, or by 5.5%, from DKK 210.4 million in 2010 to DKK 222.0 million in 2011. Research and development costs are mainly attributable to the two phase lll trials of LCP-Tacro. These costs include the finalization of the phase lll study in kidney transplant patients (stable patients, Study 3001) along with costs associated with the ongoing phase lll study in kidney transplant patients (de novo patients, Study 3002).

  • Administrative expenses decreased by DKK 4.4 million or by 8.4%, from DKK 52.2 million in 2010 to DKK 47.8 million in 2011. The reduction in cost is attributable to the continued focus on reducing overall cost.

  • During 2011, Veloxis recognized DKK 252.6 million in net loss compared to DKK 274.2 million in 2010. The net loss is in line with management's expectations for 2011, which projected a net loss of DKK 250 - 280 million.

  • As per 31 December 2011, the balance sheet reflects cash and cash equivalents of DKK 297.7 million compared to DKK 531.5 million as per 31 December 2010. The decrease in cash position reflects the changes in operating activities in 2011. The cash position is in line with management's expectations for 2011, which projected a cash position at the end of 2011 of DKK 250 - 300 million.

Conference Call



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES